Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs AJANTA PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA AJANTA PHARMA AUROBINDO PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 18.2 27.7 65.8% View Chart
P/BV x 3.9 6.8 57.6% View Chart
Dividend Yield % 0.3 0.5 51.8%  

Financials

 AUROBINDO PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
AJANTA PHARMA
Mar-19
AUROBINDO PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs8301,422 58.4%   
Low Rs527898 58.7%   
Sales per share (Unadj.) Rs333.9233.5 143.0%  
Earnings per share (Unadj.) Rs40.444.0 91.8%  
Cash flow per share (Unadj.) Rs51.852.2 99.2%  
Dividends per share (Unadj.) Rs2.509.00 27.8%  
Dividend yield (eoy) %0.40.8 47.5%  
Book value per share (Unadj.) Rs237.1255.1 92.9%  
Shares outstanding (eoy) m585.9188.02 665.7%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x2.05.0 40.9%   
Avg P/E ratio x16.826.4 63.7%  
P/CF ratio (eoy) x13.122.2 59.0%  
Price / Book Value ratio x2.94.5 63.0%  
Dividend payout %6.220.5 30.3%   
Avg Mkt Cap Rs m397,569102,081 389.5%   
No. of employees `00017.96.8 262.6%   
Total wages/salary Rs m25,8494,307 600.1%   
Avg. sales/employee Rs Th10,956.93,022.6 362.5%   
Avg. wages/employee Rs Th1,447.7633.4 228.6%   
Avg. net profit/employee Rs Th1,324.3569.1 232.7%   
INCOME DATA
Net Sales Rs m195,63620,554 951.8%  
Other income Rs m1,553211 736.8%   
Total revenues Rs m197,18920,765 949.6%   
Gross profit Rs m39,5195,664 697.7%  
Depreciation Rs m6,680721 926.7%   
Interest Rs m2,62612 22,637.9%   
Profit before tax Rs m31,7675,143 617.7%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2691,273 571.0%   
Profit after tax Rs m23,6453,870 611.0%  
Gross profit margin %20.227.6 73.3%  
Effective tax rate %22.924.8 92.4%   
Net profit margin %12.118.8 64.2%  
BALANCE SHEET DATA
Current assets Rs m153,64511,812 1,300.7%   
Current liabilities Rs m120,4293,776 3,189.0%   
Net working cap to sales %17.039.1 43.4%  
Current ratio x1.33.1 40.8%  
Inventory Days Days13577 174.7%  
Debtors Days Days6482 78.1%  
Net fixed assets Rs m103,90914,398 721.7%   
Share capital Rs m586175 334.0%   
"Free" reserves Rs m138,32222,277 620.9%   
Net worth Rs m138,90822,452 618.7%   
Long term debt Rs m1,8007 27,265.2%   
Total assets Rs m264,54426,962 981.2%  
Interest coverage x13.1444.3 2.9%   
Debt to equity ratio x00 4,407.0%  
Sales to assets ratio x0.70.8 97.0%   
Return on assets %9.914.4 69.0%  
Return on equity %17.017.2 98.8%  
Return on capital %23.823.0 103.9%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31610,682 911.1%   
Fx outflow Rs m40,5892,102 1,931.1%   
Net fx Rs m56,7278,580 661.2%   
CASH FLOW
From Operations Rs m16,2203,748 432.8%  
From Investments Rs m-28,768-2,228 1,291.2%  
From Financial Activity Rs m19,191-1,475 -1,301.4%  
Net Cashflow Rs m6,65645 14,726.5%  

Share Holding

Indian Promoters % 54.1 73.8 73.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 1.6 512.9%  
FIIs % 27.7 7.6 364.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 17.0 60.0%  
Shareholders   69,601 20,968 331.9%  
Pledged promoter(s) holding % 8.6 4.4 195.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  GLENMARK PHARMA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Momentum Moves: The Week Gone By(Momentum Moves)

Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 15, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - LUPIN COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS